Literature DB >> 25986539

Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration.

Andrew McEwen1, Laura Lawrence2, Randy Hoover2, Lloyd Stevens3, Stuart Mair3, Gill Ford1, Dylan Williams1, Stuart Wood1.   

Abstract

1. The pharmacokinetics and disposition of delafloxacin was investigated following a single intravenous (300 mg, 100 µCi) dose to healthy male subjects. 2. Mean Cmax, AUC0-∞, Tmax and t1/2 values for delafloxacin were 8.98 µg/mL, 21.31 µg h/mL, 1 h and 2.35 h, respectively, after intravenous dosing. 3. Radioactivity was predominantly excreted via the kidney with 66% of the radioactive dose recovered in the urine. Approximately 29% of the radioactivity was recovered in the faeces, giving an overall mean recovery of 94% administered radioactivity. 4. The predominant circulating components were identified as delafloxacin and a direct glucuronide conjugate of delafloxacin.

Entities:  

Keywords:  Delafloxacin; human; metabolism; quinolone

Mesh:

Substances:

Year:  2015        PMID: 25986539     DOI: 10.3109/00498254.2015.1042946

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

Authors:  Jennifer Shiu; Grace Ting; Tony Kl Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

Review 2.  Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.

Authors:  Elda Righi; Alessia Carnelutti; Antonio Vena; Matteo Bassetti
Journal:  Infect Drug Resist       Date:  2018-04-04       Impact factor: 4.003

3.  Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function.

Authors:  Randall K Hoover; Harry Alcorn; Laura Lawrence; Susan K Paulson; Megan Quintas; Sue K Cammarata
Journal:  J Clin Pharmacol       Date:  2017-12-18       Impact factor: 3.126

Review 4.  Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.

Authors:  Paul M Tulkens; Françoise Van Bambeke; Stephen H Zinner
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

Review 5.  Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  L J Scott
Journal:  Drugs       Date:  2020-08       Impact factor: 9.546

6.  Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.

Authors:  Randall Hoover; Thomas C Marbury; Richard A Preston; Megan Quintas; Laura E Lawrence; Susan K Paulson; David R Luke; Sue K Cammarata
Journal:  J Clin Pharmacol       Date:  2016-10-14       Impact factor: 3.126

Review 7.  Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Authors:  Sarah C J Jorgensen; Nicholas J Mercuro; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2018-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.